蒙药乙肝1号对HBV转染细胞表达功能的影响

Inhibition of Mongolicine Medicine "No 1 Hepatitis B" on Expression Function of Transfection Cell

目的:探讨蒙药乙肝1号抗HBV药理作用。方法:采用HBV的2.2.15细胞系作为模型,观察药物对2.2.15细胞分泌HBsAg和HBeAg的抑制效果。结果:蒙药乙肝1号30mg/ml浓度对细胞有毒,最大耐受药物浓度20mg/ml时对HBsAg抑制率为57.81％,半数有效剂量(IC_(50)为5.54±3.44mg/ml,治疗指数TI为5.42±3.42;对HBeAg的抑制率为71.64％,半数有效剂量(IC_(50))为3.69±0.01mg/ml,治疗指数(TI)为6.41±0.03mg/ml。结论:提示蒙药乙肝1号煎剂在体外有一定的抗HBV作用。

Aim: To study the pharmacological action of Mongolian medicine 'No: 1 Hepatitis B' on and-HBV. Method: Adopting toxicity test of 2. 2. 15 cell strain for screening antiviral drug to observe inhibiting action of Mongolian medicine 'No:l Hepatitis B' on 2. 2. 15 cell strain secreting HBsAg and HBeAg. Result: When the concentration of Mongolian medicine 'No: 1 Hepatitis B' arrived at 30mg/ml it had toxic action to 2. 2. 15 cell strain. When the maximal tolerable concentration was 20mg/ml the inhibitive rate to HBsAg was 57. 81%. The median effective concentration was 5. 54±3. 44mg/ml,the therapeutic Index was 5. 42±3. 42,the inhibitive rate to HBeAg was 71. 64% , the median effective concentration was 3. 69±0.0 lmg/ml, the therapeutic inedx was 6. 41± 0. 03mg/ml. Conclusion: Mongolian medicine 'No: 1 Hepatitis B' has fixed anti-HBV action in vitro.